comparemela.com

Latest Breaking News On - Clinical development excellence - Page 1 : comparemela.com

Investegate |NOVARTIS AG CHF0 50(REGD) Announcements | NOVARTIS AG CHF0 50(REGD): Patients with hidradenitis suppurativa experienced sustained efficacy and symptom improvement at one year when treated with Novartis Cosentyx®

Investegate announcements from NOVARTIS AG CHF0.50(REGD), Patients with hidradenitis suppurativa experienced sustained efficacy and symptom improvement at one year when treated with Novartis Cosentyx®

Patients with hidradenitis suppurativa experienced sustained efficacy and symptom improvement at one year when treated with Novartis Cosentyx

04.02.2023 - In two of the largest Phase III trials conducted in hidradenitis suppurativa (HS), Cosentyx (secukinumab) treatment response rates continued to improve beyond the primary endpoint analysis at Week 16 to more than 55% at Week 52, as evaluated by the .

Patients with hidradenitis suppurativa experienced

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.